Skip to main content

David Tabernero Caellas

Institutions of which they are part

Senior researcher
Liver Diseases
Vall Hebron Institut de Recerca

David Tabernero Caellas

Institutions of which they are part

Senior researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Estrategia de diagnóstico para la derivación de pacientes con infección activa por VHC desde atención primaria

IP: -
Collaborators: David Tabernero Caellas
Funding agency: GILEAD SCIENCES SLU
Funding: 48599.7
Reference: GLD17/00276
Duration: 16/01/2018 - 15/01/2020

MUTACIONES DE RESISTENCIA A LOS NUEVOS TRATAMIENTOS VHC, CLAVE PARA OPTIMIZAR LA EFICIENCIA CLÍNICA Y PRESUPUESTARIA.

IP: -
Collaborators: Carolina Gonzalez Fernandez, Marta Bes Maijo, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 172727.5
Reference: PI15/00829
Duration: 01/01/2016 - 31/12/2018

Análisis de la interacción de los virus de la hepatitis B y D con el receptor del hepatocito y estudio prospectivo de la complejidad de sus quasiespecies virales

IP: Maria Buti Ferret
Collaborators: Lluís Viladomiu Catà, Maria del Mar Riveiro Barciela, Carolina Gonzalez Fernandez, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 147015
Reference: PI14/01416
Duration: 01/01/2015 - 31/12/2017

Malalties Hepatobiliars (GRC)

IP: -
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Silvia Sauleda Oliveras, Maria Buti Ferret, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Roser Navarro García

Roser Navarro García

Infectious Diseases
Read more
Mª Carmen López  Arribas

Mª Carmen López Arribas

Research technician
Molecular Medical Imaging
Read more
Jesús Francisco Lopez Lozano

Jesús Francisco Lopez Lozano

Read more
Jorge Serra Pueyo

Jorge Serra Pueyo

Main researcher
Physiology and Pathophysiology of the Digestive Tract
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.